Ahmedabad-based Lincoln Pharmaceuticals (LPL) has registered 24 per cent growth in the revenues for the third quarter ended December 2010. The company is aiming for improved growth prospects after the restructuring of the entire business.
Speaking on the results Mahendra Patel, MD of the company said, "The restructuring of the entire business was definitely required. While in the short term it has cost us a reduction in PBT, we are confident to see positive effects of the restructuring in the long term. It will also help us concentrate on each division individually."Adding further, he said, "The launch of the two new products TINNEX injection and Pa12 will strengthen our position we are looking forward to a growth of about 25% in the next fiscal."